Drug Free Solution, Inc.

Drug Free Solution, Inc., a lifestyle company, delivers proprietary emotional wellness technology, known as Living Breath Process. Its Living Breath Process is a three-step process that combines self-analysis, breath, and language addressing various markets, including addiction/prevention, self help, emotional wellness, and lifestyle. The company also offers the Living Breath Series of programs with products, education, and services. Its Living Breath Project, through protocols, lifestyle enhancement products, training, and education, focuses on creating community wellness centers, wellness homes, and correctional facility support networks and centers that combine various offerings to diminish addiction and incarceration rates in the United States. The company was formerly known as Living Breath Project, Inc. and changed its name to Drug Free Solution, Inc. in January 2014. Drug Free Solution, Inc. is based in El Segundo, California.

Drug Free Solution, Inc. trades as DSOL on OTC. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Drug Free Solution, Inc. can be compared against peers such as Alternate Health Corp., The Cannabist Company Holdings Inc., Cynata Therapeutics Limited, iAnthus Capital Holdings, Inc., Leef Brands Inc., Medical Developments International Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $88,891, beta of -0.49, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

DSOL currently shows total debt of N/A and beta of -0.49. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.drugfreesolution.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.